REPLIGEN CORP — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Repligen completed its acquisition of BioLife Solutions on October 6, 2026. BioLife shareholders received $11.25 per share in cash plus 0.1442 Repligen shares per BioLife share. The deal adds BioLife's cell therapy biopreservation products (including CryoStor, supporting 18 approved therapies) to Repligen's bioprocessing portfolio. Financial impact details deferred to Q3 2026 earnings call.
Why this rating
Material M&A adding complementary high-margin recurring revenue business in fast-growing cell therapy market. Stock+cash consideration and product synergies support strategic fit, but deal size and integration risk moderate near-term certainty.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.